Things to know about molotinib in the treatment of myelofibrosis

Molotinib, trade nameOjjaara, is an innovative drug developed by GlaxoSmithKline. It is mainly used to treat patients with moderate or high-risk myelofibrosis accompanied by anemia. When using this medicine for treatment, patients should pay special attention to the following key matters to ensure the safety and effectiveness of the treatment process.

First, patients need to explain their allergy history to their doctor in detail. If you are allergic to molotinib or any of its ingredients, be sure to report it to your doctor in time to prevent possible risks.

Secondly, given that molotinib may interact with other drugs, patients should provide a detailed list of medications, including prescription drugs, over-the-counter drugs, nutritional supplements, and herbal medicines, before taking the drug. This helps doctors evaluate potential drug-drug interactions and adjust treatment strategies accordingly.

Furthermore, molotinib may have an impact on the patient's liver function. Therefore, during treatment, patients should undergo regular liver function tests. Seek medical help immediately if you develop signs of abnormal liver function, such as jaundice, nausea, vomiting, or abdominal pain. At the same time, patients should avoid drinking alcohol while taking molotinib to reduce the burden on the liver.

Pregnant and lactating women should consult a professional physician before using molotinib. Based on available clinical data, this drug may cause adverse effects on the fetus. Therefore, patients should use effective contraceptive measures during treatment and for one week after discontinuation of treatment. At the same time, breastfeeding is not recommended during treatment and for approximately one week after stopping the drug.

Finally, patients should pay close attention to their body's reactions. Molotinib may cause some common side effects, such as fatigue, headache, or nausea. If these symptoms persist or worsen, you should communicate with your doctor promptly. In addition, if any abnormal symptoms occur, such as continued bleeding or infection, you should also seek medical treatment immediately.

In summary, molotinib (Ojjaara) provides a new treatment option for patients with myelofibrosis and anemia. However, in order to ensure the safety and effectiveness of the treatment, patients should strictly follow the doctor's instructions during use and pay attention to the above key matters.